SCHEMBL6493367

SCHEMBL6493367

O=C(O)N1CC[C@H]2[C@@H](C1)c1cc(N=C(c3ccccc3)c3ccccc3)cc3c1N2CCOC3

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 1/20 0.33
HTR2A P28223 10/20 0.33
HTR2C P28335 10/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
KMT2A Q03164 1/20 0.32
DRD2 P14416 7/20 0.32
GRIN1 Q05586 1/20 0.32
GRIN2B Q13224 1/20 0.32
L3MBTL3 Q96JM7 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
ACACB O00763 1/20 0.31
ACACA Q13085 1/20 0.31
ACHE P22303 1/20 0.31
HTR1A P08908 1/20 0.31
DRD4 P21917 1/20 0.31
ADRA1A P35348 1/20 0.31
ADRA1B P35368 1/20 0.31
GAA P10253 1/20 0.31
CCR3 P51677 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6810428 0.79 DRD2 (0.34) HTR2AHTR2CDRD2CCR3
SCHEMBL6490580 0.79 DRD2 (0.34) HTR2AHTR2CDRD2CCR3
SCHEMBL6494306 0.79 HTR2A (0.36) HTR2AHTR2CDRD2
SCHEMBL6492716 0.79 HTR2C (0.41) HTR2AHTR2CDRD2HTR1ADRD4
SCHEMBL6501085 0.79 HTR2C (0.41) HTR2AHTR2CDRD2HTR1ADRD4
SCHEMBL6489673 0.73 USP30 (0.32)
SCHEMBL6810041 0.70 TYK2 (0.35)
SCHEMBL6504219 0.70 PIK3CA (0.36) ALDH1A1SMN1; SMN2CCR3
SCHEMBL6503483 0.69 RAF1 (0.31)
SCHEMBL5410618 0.69 CCR3 (0.39) HTR2AHTR2CDRD2CCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6849619-B2 Substituted pyridoindoles as serotonin agonists and antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2005-02-01 US disclosed
US-20040186094-A1 Substituted pyridoindoles as serotonin agonists and antagonists BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-09-23 US disclosed
US-6699852-B2 ANTISEROTONIN AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS; ANTIDEPRESSANTS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-03-02 US disclosed
US-20020173503-A1 Substituted pyridoindoles as serotonin agonists and antagonists BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-11-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173503-A1 Substituted pyridoindoles as serotonin agonists and antagonists HTR1A, HTR1B, HTR7 KDM4E 2300/4885ALDH1A1 2258/4885HTR2A 21/4885
US-20040186094-A1 Substituted pyridoindoles as serotonin agonists and antagonists HTR1A, HTR1B, HTR7 KDM4E 2300/4885ALDH1A1 2258/4885HTR2A 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.